Hemophilia without prophylaxis: Assessment of joint range of

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet

Hemophilia A and B: An Overview

Advances in Hemophilia A Management - Advances in Pediatrics

Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort - The Lancet Haematology

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Severe Hem A Patients Showing Bleeds, Physical Limits With Prophylaxis

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: a 3-year follow-up study in Senegal, West Africa

Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial - ISTH Congress Abstracts